Aberrant RBMX Expression Relevant for Cancer Prognosis and Immunotherapy Response
01-17-2024“In the future, targeting of RBMX may be a novel method in cancer therapy.”
Listen to an audio version of this press release
BUFFALO, NY- January 17, 2024 – A new research paper was published inAging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response.”
Cancer accounts for the highest rates of morbidity and mortality worldwide. RNA binding motif protein X-linked (RBMX) is a nuclear RNA-binding protein, associated with certain types of cancer by participating in the integration of sister chromatids and a combination of ribonucleoprotein complexes. However, the specific role of RBMX in cancer immunity remains unknown.
In this new study, researchers Yilei Sheng, Kunjian Lei, Chengpeng Sun, Jia Liu, Zewei Tu, Xingen Zhu, and Kai Huang from Nanchang University, The Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, JXHC Key Laboratory of Neurological Medicine, and Yale School of Medicine present the aberrant expression levels, single-cell distributions, effective prognostic roles, immune cell infiltration associations, and immunotherapy responses of RBMX as a biomarker in various types of cancer. Moreover, they validate the aberrant expression of RBMX in clinical cancer samples.
“[...] a pan-cancer analysis is necessary for the identification of novel biological targets and biomarkers involved in carcinogenesis, cancer progression, and immunotherapy response. Such knowledge would improve the precision of cancer therapy.”
The researchers also evaluated the relationships between RBMX expression and myeloid-derived suppressor cells in clinical samples by immunofluorescent staining. Results showed that knockdown of RBMX can impair the proliferation, migration, and invasion of liver cancer cells. Finally, the team indicated that RBMX may play an immunoregulatory role in cancer progression, affecting the therapeutic effects of immune checkpoint inhibitors in patients with cancer.
“In conclusion, we performed an integrated analysis of RBMX, revealing its effective role in predicting cancer prognosis and response to immunotherapy. Abnormal expression of RBMX is associated with immune regulation, prognosis, the tumor microenvironment, immune cell infiltration, MSI, and TMB. The results of this study indicated that RBMX may play an independent role in clinical diagnosis and prediction.”
Read the full paper: DOI:https://doi.org/10.18632/aging.205363
Corresponding Authors: Zewei Tu, Xingen Zhu, Kai Huang
Corresponding Emails:401441619022@email.ncu.edu.cn, ndefy89006@ncu.edu.cn, kaihuang@ncu.edu.cn
Keywords: RBMX, cancer prognosis, immunotherapy response, proliferation, invasion
Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.https://doi.org/10.18632/aging.205363
About Aging-US:
Cancer and aging are two sides of age-related tumorigenesis.
The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.
The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, Apple, SoundCloud, and available wherever you listen to podcasts
For media inquiries, please contact media@impactjournals.com.